Table Info

Flexible linkers (n, m = 0, 1, 2, 3, 4, etc.)	Relatively rigid linkers	Click chemistry based linkers
alkane	piperidine/benzene	triazole
alkyne-alkane	triazole-PEG
PEG	benzene	(CLIPTAC)
PEG-alkane
amide	azobenzene (photoswitchable)

Declarations

Author contributions

All authors contributed to the conception and preparation of this review. AZ prepared the first draft of the manuscript, and all authors contributed to the writing and development of additional sections. All authors contributed to manuscript revision and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

The study was funded by RSF grant 19-74-10022 to EB, and performed according to the Russian Government Program of Competitive Growth of Kazan Federal University. The funder(s) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Bulatov E, Zagidullin A, Valiullina A, Sayarova R, Rizvanov A. Small molecule modulators of RING-type E3 ligases: MDM and Cullin families as targets. Front Pharmacol. 2018;9:450. [DOI] [PubMed] [PMC]

Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11:611–7. [DOI] [PubMed] [PMC]

Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discov. 2019;18:949–63. [DOI] [PubMed]

Xi M, Chen Y, Yang H, Xu H, Du K, Wu C, et al. Small molecule PROTACs in targeted therapy: an emerging strategy to induce protein degradation. Eur J Med Chem. 2019;174:159–80. [DOI] [PubMed]

Nowak RP, DeAngelo SL, Buckley D, He Z, Donovan KA, An J, et al. Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat Chem Biol. 2018;14:706–14. [DOI] [PubMed] [PMC]

Burslem GM, Smith BE, Lai AC, Jaime-Figueroa S, McQuaid DC, Bondeson DP, et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem Biol. 2018;25:67–77.e3. [DOI] [PubMed] [PMC]

Buckley DL, Raina K, Darricarrere N, Hines J, Gustafson JL, Smith IE, et al. HaloPROTACS: use of small molecule PROTACs to induce degradation of halotag fusion proteins. ACS Chem. Biol. 2015;10:1831–7. [DOI] [PubMed] [PMC]

Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, et al. Targeting BCRABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation. Cancer Res. 2019;79:4744–53. [DOI] [PubMed] [PMC]

Itoh Y, Ishikawa M, Naito M, Hashimoto Y. Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. J Am Chem Soc. 2010;132:5820–6. [DOI] [PubMed]

10.

Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, et al. Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer. J Med Chem. 2019;62:941–64. [DOI] [PubMed]

11.

Lai AC, Toure M, Hellerschmied D, Salami J, Jaime-Figueroa S, Ko E, et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016;55:807–10. [DOI] [PubMed] [PMC]

12.

Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348:1376–81. [DOI] [PubMed] [PMC]

13.

Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 2001;98:8554–9. [DOI] [PubMed] [PMC]

14.

Yang J, Li Y, Aguilar A, Liu Z, Yang CY, Wang S. Simple structural modifications converting a Bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degrader. J Med Chem. 2019;62:9471–87. [DOI] [PubMed] [PMC]

15.

Wu H, Yang K, Zhang Z, Leisten ED, Li Z, Xie H, et al. Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity. J Med Chem. 2019;62:7042–57. [DOI] [PubMed]

16.

Zoppi V, Hughes SJ, Maniaci C, Testa A, Gmaschitz T, Wieshofer C, et al. Iterative design and optimization of initially inactive Proteolysis Targeting Chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel-Lindau (VHL) based dual degrader probe of BRD9 and BRD7. J Med Chem. 2019;62:699–726. [DOI] [PubMed] [PMC]

17.

England CG, Luo H, Cai W. HaloTag technology: a versatile platform for biomedical applications. Bioconjug Chem. 2015;26:975–86. [DOI] [PubMed] [PMC]

18.

Tinworth CP, Lithgow H, Dittus L, Bassi ZI, Hughes SE, Muelbaier M, et al. PROTAC-mediated degradation of Bruton’s tyrosine kinase is inhibited by covalent binding. ACS Chem Biol. 2019;14:342–7. [DOI] [PubMed]

19.

Hu J, Hu B, Wang M, Xu F, Miao B, Yang CY, et al. Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER). J Med Chem. 2019;62:1420–42. [DOI] [PubMed]

20.

Li Y, Yang J, Aguilar A, McEachern D, Przybranowski S, Liu L, et al. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression. J Med Chem. 2019;62:448–66. [DOI] [PubMed] [PMC]

21.

Qin C, Hu Y, Zhou B, Fernandez-Salas E, Yang CY, Liu L, et al. Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression. J Med Chem. 2018;61:6685–704. [DOI] [PubMed] [PMC]

22.

Tanaka M, Roberts JM, Seo HS, Souza A, Paulk J, Scott TG, et al. Design and characterization of bivalent BET inhibitors. Nat Chem Biol. 2016;12:1089–96. [DOI] [PubMed] [PMC]

23.

Gadd MS, Testa A, Lucas X, Chan KH, Chen W, Lamont DJ, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017;13:514–21. [DOI] [PubMed] [PMC]

24.

Yang K, Song Y, Xie H, Wu H, Wu YT, Leisten ED, et al. Development of the first small molecule histone deacetylase 6 (HDAC6) degraders. Bioorg Med Chem Lett. 2018;28:2493–7. [DOI] [PubMed]

25.

Sun Y, Zhao X, Ding N, Gao H, Wu Y, Yang Y, et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res. 2018;28:779–81. [DOI] [PubMed] [PMC]

26.

Chen H, Chen F, Liu N, Wang X, Gou S. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway. Bioorg Chem. 2018;81:536–44. [DOI] [PubMed]

27.

Wurz RP, Dellamaggiore K, Dou H, Javier N, Lo MC, McCarter JD, et al. A “Click chemistry platform” for the rapid synthesis of bispecific molecules for inducing protein degradation. J Med Chem. 2018;61:453–61. [DOI] [PubMed]

28.

Lebraud H, Wright DJ, Johnson CN, Heightman TD. Protein degradation by in-cell self-assembly of proteolysis targeting chimeras. ACS Cent Sci. 2016;2:927–34. [DOI] [PubMed] [PMC]

29.

Xia LW, Ba MY, Liu W, Cheng W, Hu CP, Zhao Q, et al. Triazol: a privileged scaffold for proteolysis targeting chimeras. Future Med Chem. 2019;11:2919–73. [DOI] [PubMed]

30.

Bian J, Ren J, Li Y, Wang J, Xu X, Feng Y, et al. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity. Bioorg Chem. 2018;81:373–81. [DOI] [PubMed]

31.

Reynders M, Matsuura BS, Bérouti M, Simoneschi D, Marzio A, Pagano M, et al. PHOTACs enable optical control of protein degradation. Sci Adv. 2020;6:eaay5064. [DOI] [PubMed] [PMC]

32.

Pfaff P, Samarasinghe KTG, Crews CM, Carreira EM. Reversible spatiotemporal control of induced protein degradation by bistable PhotoPROTACs. ACS Cent Sci. 2019;5:1682–90. [DOI] [PubMed] [PMC]

33.

Jin YH, Lu MC, Wang Y, Shan WX, Wang XY, You QD, et al. Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown. J Med Chem. 2020;63:4644–54. [DOI] [PubMed]

34.

Teichmann E, Hecht S. Shining a light on proteolysis targeting chimeras. ACS Cent Sci. 2019;5:1645–7. [DOI] [PubMed] [PMC]

35.

Roberts BL, Ma ZX, Gao A, Leisten ED, Yin D, Xu W, et al. Two-stage strategy for development of proteolysis targeting chimeras and its application for estrogen receptor degraders. ACS Chem Biol. 2020;15:1487–96. [DOI] [PubMed]

36.

Testa A, Hughes SJ, Lucas X, Wright JE, Ciulli A. Structure-based design of a macrocyclic PROTAC. Angew Chem Int Ed Engl. 2020;59:1727–34. [DOI] [PubMed] [PMC]

37.

Cyrus K, Wehenkel M, Choi EY, Han HJ, Lee H, Swanson H, et al. Impact of linker length on the activity of PROTACs. Mol Biosyst. 2011;7:359–64. [DOI] [PubMed] [PMC]

38.

Steinebach C, Lindner S, Udeshi ND, Mani DC, Kehm H, Köpff S, et al. Homo-PROTACs for the chemical knockdown of Cereblon. ACS Chem Biol. 2018;13:2771–82. [DOI] [PubMed]

39.

Crew AP, Raina K, Dong H, Qian Y, Wang J, Vigil D, et al. Identification and characterization of von hippellindau-recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1. J Med Chem. 2018;61:583–98. [DOI] [PubMed]

40.

Ohoka N, Okuhira K, Ito M, Nagai K, Shibata N, Hattori T, et al. In vivo knockdown of pathogenic proteins via specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs). J Biol Chem. 2017;292:4556–70. [DOI] [PubMed] [PMC]

41.

Shibata N, Miyamoto N, Nagai K, Shimokawa K, Sameshima T, Ohoka N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017;108:1657–66. [DOI] [PubMed] [PMC]

42.

Demizu Y, Shibata N, Hattori T, Ohoka N, Motoi H, Misawa T, et al. Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand. Bioorg Med Chem Lett. 2016;26:4865–9. [DOI] [PubMed]

43.

Maniaci C, Hughes SJ, Testa A, Chen W, Lamont DJ, Rocha S, et al. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation. Nat Commun. 2017;8:830. [DOI] [PubMed] [PMC]

44.

Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, et al. Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem. 2018;61:462–81. [DOI] [PubMed] [PMC]

45.

Drummond ML, Williams CI. In Silico modeling of PROTAC-mediated ternary complexes: validation and application. J Chem Inf Model. 2019;59:1634–44. [DOI] [PubMed]

46.

Buhimschi AD, Armstrong HA, Toure M, Jaime-Figueroa S, Chen TL, Lehman AM, et al. Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation. Biochemistry. 2018;57:3564–75. [DOI] [PubMed]

47.

Zorba A, Nguyen C, Xu Y, Starr J, Borzilleri K, Smith J, et al. Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc Natl Acad Sci USA. 2018;115:E7285–92. [DOI] [PubMed] [PMC]

48.

Ma B, Tsai CJ, Haliloğlu T, Nussinov R. Dynamic allostery: linkers are not merely flexible. Structure. 2011;19:907–17. [DOI] [PubMed] [PMC]

49.

Zengerle M, Chan KH, Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem Biol. 2015;10:1770–7. [DOI] [PubMed] [PMC]

50.

Cyrus K, Wehenkel M, Choi EY, Lee H, Swanson H, Kim KB. Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs. ChemMedChem. 2010;5:979–85. [DOI] [PubMed] [PMC]

51.

Smith BE, Wang SL, Jaime-Figueroa S, Harbin A, Wang J, Hammanet BD, et al. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat Commun. 2019;10:131. [DOI] [PubMed] [PMC]

52.

Farnaby W, Koegl M, Roy MJ, Whitworth C, Diers E, Trainor N, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol. 2019;15:672–80. [DOI] [PubMed] [PMC]

53.

An S, Fu L. Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018;36:553–62. [DOI] [PubMed] [PMC]

54.

Itoh Y. Chemical protein degradation approach and its application to epigenetic targets. Chem Rec. 2018;18:1681–700. [DOI] [PubMed]